Scientists Engineer Implantable Constructs to Support Long-Term Insulin-Producing Cell Transplants

Transplanting insulin-producing islet cells offers potential as a Type 1 diabetes therapy, but the approach faces significant hurdles. One critical problem is that transplanted cells often struggle to survive when placed under the skin or in other locations outside the liver. Without adequate blood vessel formation and a supportive environment, transplanted islets typically fail to function well over time.

To address these challenges, researchers engineered vascularized endocrine constructs (VECs) by combining pancreatic islets with human blood vessel-building cells in a specially designed scaffold called Amniogel. This scaffold is made from amniotic membrane material and is designed to be compatible with good manufacturing practices—an important step toward eventual clinical use.

The Amniogel scaffold contains natural signals that help islet cells stay viable and function properly. It also encourages the vessel-building cells to form networks of new blood vessels. These networks help islet cells communicate better with each other and restore their ability to sense glucose and release insulin in response to blood sugar changes.

When researchers implanted these engineered constructs under the skin of diabetic mice, the results were encouraging. The implanted tissue developed new blood vessels that connected to the animals' existing circulation. The transplants then reestablished normal blood sugar levels, outperforming similar constructs that lacked the vascularization component.

In laboratory studies, the Amniogel scaffold also showed a potential immune-protective effect. It slowed the migration of certain immune cells known to damage islet cells in Type 1 diabetes, suggesting it might help protect transplanted tissue during the critical early period after implantation.

While these findings are promising, it is important to note that this work represents early-stage research conducted in mice. The combination of vascularization support, an immune-protective scaffold, and a scalable manufacturing approach suggests a potentially durable path toward cell replacement therapy for Type 1 diabetes. However, significant additional work—including safety and efficacy studies in larger animals and ultimately in people—will be necessary before this approach can be tested in patients. These results do not indicate a timeline for clinical availability.

Source: Trends in biotechnology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.